With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs.

Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves:
•	Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications
•	Site-specific conjugation technology
•	Monoclonal antibodies (mAbs)
•	Highly selective, disease-targeting small molecules

The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.

Therapeutics

Biotechnology

Byondis

Ronald Smulders

Wim Dokter

Marieke van Gent

Aad van de Leur

Gerrit Voortman

Norbert Koper

The Business Development and Strategic Operations team at Byondis is responsible for identifying and pursuing growth opportunities, forging strategic partnerships, and optimizing company operations to enhance the development and delivery of precision medicines. This team leverages market insights, develops strategic initiatives, and oversees business operations to ensure alignment with the company's mission of providing innovative treatments for cancers and autoimmune diseases.

Business Development and Strategic Operations

Leadership Team

Scientific Research and Development

Business Development and Strategic Operations

About

Team members

Other teams at Byondis

Leadership Team

Scientific Research and Development